Shoukry Naglaa H
Centre de Recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.
Département de médecine, Faculté de médecine, Université de Montréal, Montréal, QC, Canada.
Front Immunol. 2018 Jun 28;9:1480. doi: 10.3389/fimmu.2018.01480. eCollection 2018.
The development of vaccines that protect against persistent hepatitis C virus (HCV) infection remain a public health priority. The broad use of highly effective direct-acting antivirals (DAAs) is unlikely to achieve HCV elimination without vaccines that can limit viral transmission. Two vaccines targeting either the antibody or the T cell response are currently in preclinical or clinical trials. Next-generation vaccines will likely involve a combination of these two strategies. This review summarizes the state of knowledge about the immune protective role of HCV-specific antibodies and T cells and the current vaccine strategies. In addition, it discusses the potential efficacy of vaccination in DAA-cured individuals. Finally, it summarizes the challenges to vaccine development and the collaborative efforts required to overcome them.
开发能够预防持续性丙型肝炎病毒（HCV）感染的疫苗仍然是公共卫生领域的一项优先任务。如果没有能够限制病毒传播的疫苗，广泛使用高效直接抗病毒药物（DAA）不太可能实现丙型肝炎病毒的消除。目前有两种分别针对抗体或T细胞反应的疫苗正处于临床前或临床试验阶段。下一代疫苗可能会结合这两种策略。本综述总结了关于HCV特异性抗体和T细胞的免疫保护作用以及当前疫苗策略的知识现状。此外，还讨论了在接受DAA治疗的个体中接种疫苗的潜在疗效。最后，总结了疫苗开发面临的挑战以及克服这些挑战所需的合作努力。
